Stock Market Today (LIVE): Middle East Breakthrough Sends Futures Higher as Crude Crumbles and Rate Cut hopes Revive

Today’s Highlights

• Apple Set to Launch New Siri App
• Futures Rise as Hormuz Reopening Nears

📌 Top story – scroll down for more updates

Chewy Soars as Record FCF Hits $232 Million

8:45 am – CHWY +10.23% in pre-market trading

Chewy (CHWY +13.75%) achieved growth in active customers and cash flow but posted lower GAAP earnings year over year. Revenue increased slightly to $3.26 billion while adjusted EBITDA rose 30.4% in the quarter. Management expects continued profitable growth and margin expansion in fiscal 2026, though no specific guidance was provided.

Expand

NYSE: CHWY

Chewy

Today’s Change

(13.75%) $3.23

Current Price

$26.68

Key Data Points

Market Cap

$9.7B

Day’s Range

$25.01 - $26.77

52wk Range

$22.74 - $48.62

Volume

270K

Avg Vol

7.9M

Gross Margin

28.58%

Merck’s $6.7B Terns Deal Targets 2028 Patent Risk

8:00 am – MRK +0.42%, TERN +5.34% in pre-market trading

Merck (MRK +0.60%) announced Wednesday a definitive agreement to acquire clinical-stage biotech Terns Pharmaceuticals (TERN +5.24%) for $6.7 billion. The all-cash deal, priced at $53 per share, aims to secure Terns’ lead candidate, TERN-701, an oral allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML). Merck CEO Rob Davis is moving aggressively to diversify the company’s oncology portfolio as its mega-blockbuster Keytruda–which generated $31.7 billion in 2025 (nearly half of total revenue)–approaches its 2028 U.S. patent expiration. The transaction is expected to close in the second quarter of 2026, resulting in a one-time charge of approximately $5.8 billion.

• Clinical Differentiation: TERN-701 is currently in the CARDINAL Phase 1/2 trial, with data presented in late 2025 showing a 75% molecular response rate. Merck believes the drug could be “best-in-disease,” offering better safety and convenience (no food restrictions) compared to Novartis’s (NVS +0.35%) rival therapy, Scemblix.
• Structural Reorg: The acquisition follows Merck’s February 2026 decision to split its “Human Health” business into two stand-alone units: Oncology (led by Jannie Oosthuizen) and Specialty, Pharma & Infectious Diseases (led by Sanofi veteran Brian Foard). This restructuring is designed to streamline the launch of over 20 anticipated “blockbuster” growth drivers by 2030.

Expand

NYSE: MRK

Merck

Today’s Change

(0.60%) $0.69

Current Price

$116.37

Key Data Points

Market Cap

$288B

Day’s Range

$114.02 - $116.54

52wk Range

$73.31 - $125.14

Volume

172K

Avg Vol

12M

Gross Margin

74.21%

Dividend Yield

2.85%

This Morning’s Breakfast News

7:30 am – BRZE +22.64% in pre-market trading

Braze (BRZE +14.32%) popped 20% overnight, after the Rule Breakers recommendation beat fourth-quarter revenue expectations with a 28% jump year over year (YoY) to $205 million. Operating income came in 84% higher than last year’s comparable quarter, as the company’s communications tools attracted 13.6% more net customers.

• “Early in fiscal 2027, we passed $800 million in annual recurring revenue”: CEO William Magnuson spoke of organic revenue growing for the third straight quarter, as remaining performance obligations broke through the trillion-dollar level.
• 2027 revenue between $884 million and $889 million: Management expects 20% revenue growth in fiscal 2027, starting with around $205 million in the first quarter. Investors should watch Braze’s dollar-based net retention rate, which declined YoY.

ICYMI: Tuesday’s Scoreboard

7:00 am – NUE unchanged in pre-market trading

Nucor (NUE +1.32%) was the subject of the latest Scoreboard video.

Abel’s First Deal Is a Perfect Capital Fit

6:15 am – BRKB +0.46% in pre-market trading

By Buck Hartzell

Berkshire Hathaway (BRKB +0.47%) just inked a 10-year strategic partnership with Tokio Marine. Berkshire subsidiary National Indemnity will invest $1.8 billion to purchase 2.49% of Tokio Marine Holdings. They can increase their ownership up to 9.9% of Tokio’s shares through open market purchases.

Tokio has a proven acquisition track record and as everyone knows, Berkshire has plenty of capital. This seems like a good match and it’s the first deal under Greg Abel. It’s nice to see Mr. Abel start to put some of that cash hoard to work!

Expand

NYSE: BRKB

Berkshire Hathaway

Today’s Change

(0.47%) $2.23

Current Price

$481.56

Key Data Points

Market Cap

$1.0T

Day’s Range

$480.72 - $482.91

52wk Range

$455.19 - $542.07

Volume

8.3K

Avg Vol

4.8M

Gross Margin

23.63%

Apple Reboots Siri as a Conversational AI App

6:00 am – AAPL +0.62% in pre-market trading

As it works to restructure its AI offerings, Apple (AAPL +1.19%) is testing a stand-alone app version of its Siri AI assistant – set to be launched at its annual Worldwide Developers Conference in June, reports Bloomberg.

• “Ask Siri” button coming to iOS 27?: Delayed from last year, Apple promised the new Siri would launch in 2026, and it’s likely to integrate across Mac and iPhone products – with access to personal data, including messages and emails.
• AI chatbot format: The new Siri is expected to offer users a conversational, chat-like, interface using voice and text – to counteract the growing dominance of tools like ChatGPT.

Expand

NASDAQ: AAPL

Apple

Today’s Change

(1.19%) $3.00

Current Price

$254.64

Key Data Points

Market Cap

$3.7T

Day’s Range

$254.00 - $254.82

52wk Range

$169.21 - $288.62

Volume

45K

Avg Vol

47M

Gross Margin

47.33%

Dividend Yield

0.41%

Arm Launches First-Ever Chip in Historic Pivot

5:30 am – ARM +12.85% in pre-market trading

Arm Holdings (ARM +11.70%) shattered its 35-year business model Tuesday, transitioning from a pure-play intellectual property licensor to a direct chip manufacturer. At its “Arm Everywhere” event in San Francisco, CEO Rene Haas unveiled the Arm AGI CPU, the company’s first-ever physical silicon product designed specifically for “agentic” AI infrastructure. Meta Platforms (META +1.33%) is the lead development partner and flagship customer, with OpenAI, Cloudflare, and SAP also signed on as early adopters. While the move puts Arm in direct competition with its own licensees–including Nvidia, Amazon, and Microsoft–investors cheered the shift. After-hours, the stock jumped 6% as Haas projected the new silicon business would drive total annual revenue to $25 billion within five years, a five-fold increase from current levels.

• The 136-Core Powerhouse: Manufactured on TSMC’s 3nm process, the AGI CPU features up to 136 Neoverse V3 cores and is designed to deliver 2x the performance-per-watt of traditional x86 racks, potentially saving data center operators billions in energy costs.
• Economic Pivot: By selling physical chips rather than just blueprints, Arm can capture up to $500 in gross profit per unit compared to the roughly $10 to $100 it typically earns in royalties, a massive expansion of its capture-of-value in the AI stack.

Expand

NASDAQ: ARM

Arm Holdings

Today’s Change

(11.70%) $15.79

Current Price

$150.75

Key Data Points

Market Cap

$143B

Day’s Range

$148.21 - $151.75

52wk Range

$80.00 - $183.16

Volume

126K

Avg Vol

6M

Gross Margin

94.84%

Before the Opening Bell

5:15 am

Stock futures are climbing Wednesday morning as global markets react to a potential diplomatic breakthrough in the Middle East. Reports from the AP and New York Times indicate the Trump administration has delivered a 15-point peace plan to Tehran via Pakistani intermediaries, aiming for a 30-day ceasefire and the reopening of the Strait of Hormuz. While Iran has publicly downplayed claims of “direct talks,” the prospect of an off-ramp has triggered a massive liquidation of the “war premium” in energy markets. Brent crude plummeted nearly 6% to trade below $95 per barrel, providing a significant relief valve for a market previously bracing for $150 oil and a prolonged inflationary shock.

• The 15-Point Framework: The proposal reportedly includes strict curbs on uranium enrichment and missile development in exchange for full sanctions relief and U.S. assistance in developing a civilian nuclear energy program at Bushehr.
• Economic Data Pivot: Beyond geopolitics, traders are eyeing February’s import and export price figures due later today. With fuel import prices already trending lower in January, any further cooling in these metrics could bolster the case for a more accommodative Federal Reserve policy later this spring.